Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis

Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis

Infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), is widely used in treating inflammatory bowel diseases (IBD), including ulcerative colitis (UC). While generally well-tolerated, infliximab is associated with rare but significant adverse effects, including autoimmune h...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerolamo Bevivino, Patrizio Scarozza, Michela Di Fonzo, Giulia Zerboni, Federico Iacopini
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Medicine
Subjects:
infliximab
hemolytic anemia
ulcerative colitis
autoimmune disorders
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1548321/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items